hVIVO Plc

More and more companies developing treatments and vaccines for infectious diseases are seeing the value of incorporating human challenge trials in their development programs, given their potential to

The executives we surveyed on the clinical trial landscape identified several sweeping trends that are expected to drive change over the coming year. As in so many spheres, data, digital technology an

British specialist contract research organization hVIVO Plc has been working in the field of vaccine development in one form or another since its germination in 1946. Human challenge studies -- the

The Australian biotech company, ENA Respiratory, is progressing its fast-acting nasal spray for the prevention of COVID-19 and other respiratory viral infections and hopes to explore partnerships for